US biotech company Advanced Cell Technology said Monday it was cleared by the government to start its second trial using human embryonic stem cells to treat blindness, this time in older people.
The trial will examine the therapy’s ability to safely treat people with a condition known as dry age-related macular degeneration, the most common form of irreversible vision loss in people over age 60.
There is currently no cure for the disease, which affects around 10-15 million Americans and another 10 million people in Europe, the company said.
The Food and Drug Administration cleared the Massachusetts-based company in November to begin a similar trial on patients with a less common form of juvenile vision loss, known as Stargardt’s disease.
“ACT is now the first company to receive FDA clearance for two hESC (human embryonic stem cell) trials, and is now a true translational leader in the field of regenerative medicine,” said chief executive Gary Rabin.
“It marks a major step forward, not just within the stem cell sector, but, potentially for modern healthcare techniques.”
The company hopes to begin the US clinical trials in the coming months, and intends to seek approval for similar trials in Europe. The US and European market for such a treatment amounts to 25 to 30 billion dollars, it said.
“We are moving ahead aggressively to seek regulatory clearance from the European Medicines Agency to conduct clinical trials in Europe,” said Edmund Mickunas, ACT?s Vice President of Regulatory Affairs.
ACT’s announcement marks the third such trial of embryonic stem cells in human patients, after US company Geron broke new ground in October last year with the first-ever attempt to use the therapy on a human patient with spinal cord injury.
Embryonic stem cell research has been a controversial field ever since the first such stem cells were isolated more than 12 years ago. Critics oppose the research because it involves the destruction of human embryos.
However scientists say the cells offer great promise in treating Parkinson’s disease, diabetes and a variety of other illnesses.
Like the other trials involving human patients, the first step in ACT’s Phase I and II trials is to assess whether the therapy is safe before moving on to testing how well it works.
Bob Lanza, chief scientist at ACT, said that trials using the technique on animals have shown no evidence of complication or tumors.
“In a rat model of macular degeneration, we have seen a remarkable improvement in visual performance over untreated animals, without any adverse effects,” said Lanza.
Twelve patients will enroll in the study at various US sites including the University of California, Los Angeles (UCLA) and Stanford University.
The therapy uses retinal pigment epithelial (RPE) cells derived from human embryonic stem cells to replace RPE cells that have broken down in patients with the disease.
Dry age-related macular degeneration, the type that occurs in 90 percent of cases, causes a deterioration in central vision when RPE cells in the patient’s macula, in the center of the retina, lose their ability to function.
Patients often experience blurring in the center of their field of vision, while peripheral view remains intact.
Dry AMD gets progressively worse, while the other type, known as wet AMD, does not advance in stages. Wet AMD is caused by abnormal blood vessels which leak fluid behind the macula, causing a quicker loss of central vision.
“As the population ages, the incidence of AMD is expected to double over the next 20 years, further exacerbating this unmet medical need,” Lanza said.
Before Trump eyed Greenland: Here’s what happened last time the US bought a large chunk of the Arctic
Editor’s note: Reports that President Donald Trump has urged aides to look into buying Greenland make us think of the last time the United States bought a major territory in the Arctic: the purchase of Alaska from Russia in 1867. Two years ago, we asked William L. Iggiagruk Hensley, a visiting professor at the University of Alaska Anchorage, to write about that historic sale.
‘That is ridiculous’: Andrew Gillum obliterates Santorum for claiming guns aren’t ‘problem’ in mass shootings
CNN contributor Andrew Gillum called conservative pundit Rick Santorum "ridiculous" on Sunday for suggesting that guns are not the problem in mass shootings.
During a CNN discussion on gun control, Santorum criticized calls from Democratic candidates for the government to buy back assault-style weapons in addition to banning them.
"The truth is something has to give," Gillum said. "The stranglehold that the NRA seems to have over Congress, over Washington, D.C., in my opinion, is insane. How can we put the priorities of one interest group above the safety, the security of the American people?"
CNN’s Jake Tapper confronts Trump adviser Navarro with long list of experts calling him a disaster
In a highly contentious interview on CNN's "State of the Union", host Jake Tapper confronted Donald Trump's top economic adviser, Peter Navarro, with a seemingly endless list of economists, analysts and business publications who believe he and his economic advice have both been a disaster and that he is not being straight with the public.
After refusing multiple times to concede that President Donald Trump's trade war -- and accompanying tariffs -- are having any effect on an economy that many financial prognosticators believe is headed towards a recession, Tapper confronted the White House adviser with the list of his critics -- including the Wall Street Journal.